Access Biologicals Completes the First-ever Commercially Available COVID-19 Seroconversion Panel to Confirm SARS-CoV-2 Antibody Assays

PR Newswire | September 07, 2020

Access Biologicals, a market leader in the collection and manufacturing of biologicals products, today announced it has completed the first-ever commercially available COVID-19 seroconversion panel to confirm the presence of anti-SARS-CoV-2 antibodies. Efforts to contain the spread of COVID-19 rely in part on serological tests to identify the presence of anti-SARS-CoV-2 antibodies in people who have had the illness. Until now, however, many of these tests have been developed rapidly and without the independent data to help assess their analytical performance and enable comparisons between different testing methods. With Access Biologicals' seroconversion panel, diagnostic manufacturers, clinical laboratories and researchers will have a reliable benchmark against which they can develop, validate and troubleshoot other COVID-19 serological assays and testing. "An effective, sensitive and specific way to identify and confirm the SARS-CoV-2 infection is urgently needed," said Mike Crowley, Managing Director Access Biologicals. "Our COVID-19 seroconversion panel will help serological assays bridge the gap through precise validation, establishing sensitivity and helping determine the pre-seroconversion window period, which is the time after infection and before seroconversion, when antibodies appear." Collected in a longitudinal series, the Access Biologicals COVID-19 seroconversion panel consists of 14 members (units) of a unique human plasma sample drawn from a single donor during a developing SARS-CoV-2 infection. The panel illustrates the onset and decline of IgM, IgG and Ig total SARS-CoV-2 virus antibody titers over a period of 87 days.

Spotlight

Since its discovery, RNAi has rapidly become an essential tool for interrogating gene function. Over the last decade, Dharmacon’s toolbox has expanded to include synthetic siRNA chemically-modified for high performance and specificity, shRNAs driven from your choice of promoter or the ability to switch expression on and off, long nonconding RNA (lncRNA) tools for detection and knockdown, and custom RNA synthesis with an astonishing number of possible chemical modifications. We are proud to support your success!

Spotlight

Since its discovery, RNAi has rapidly become an essential tool for interrogating gene function. Over the last decade, Dharmacon’s toolbox has expanded to include synthetic siRNA chemically-modified for high performance and specificity, shRNAs driven from your choice of promoter or the ability to switch expression on and off, long nonconding RNA (lncRNA) tools for detection and knockdown, and custom RNA synthesis with an astonishing number of possible chemical modifications. We are proud to support your success!

Related News

MEDICAL

Zynex Recognized as Fourth Largest Biotechnology/Bioscience Company in Colorado

Zynex, Inc. | March 24, 2022

Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the Denver Business Journal has recognized Zynex as the fourth largest Biotechnology/Bioscience public company in Colorado based on number of companywide employees as of November 1, 2021. 2021 was a strong year for us with growth on the top and bottom lines, In 2022, we expect sales rep growth and productivity to improve and are seeing momentum in order growth as the economy normalizes post COVID-19. We are positioned for another solid year of revenue growth." Thomas Sangaard, CEO and founder of Zynex Inc. About Denver Business Journal American City Business Journals (ACBJ) is the largest publisher of metropolitan business newsweeklies in the United States, with 44 business publications across the country reaching more than 3.6 million readers each week. About Zynex, Inc. Zynex, founded in 1996, develops, manufactures, markets and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis and laser-based pulse oximetry monitoring systems for use in hospitals.

Read More

INDUSTRY OUTLOOK

Andelyn Biosciences Selects TetraScience as a Strategic Partner for Innovation in Therapeutics Development and Manufacturing

Andelyn Biosciences | August 26, 2021

TetraScience, the R&D Data Cloud company, announced today that Andelyn Biosciences, Inc. has selected the Tetra Data Platform (TDP) to build a cloud-native development and manufacturing service for its customers. As part of an Andelyn Biosciences initiative to create a Connected Plant that harmonizes data from building and facilities, process and manufacturing, and lab instrument sources, TDP will enable better compliance, easier analysis, faster decisions, and more agile operations. Additionally, Andelyn customers will benefit from secure, convenient access to harmonized data that is prepared for analytics and visualization. As a Contract Development and Manufacturing Organization (CDMO) for cell and gene therapies, Andelyn must remain GMP-compliant and increase efficiency while leading the industry in the innovative services they provide to customers. By launching a Connected Plant, Andelyn will gain autonomous operation, predictive capabilities, improved process monitoring and control, and increased data integrity. "Andelyn has been a pioneer in gene therapy with a 15-year history accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients," said Bryan J. Holmes, Vice President, Information Technology at Andelyn Biosciences. "Together with TetraScience, we're transforming how we work with our clients, utilizing fully-digitized, cloud-native services to help connect all the plant and lab data created during complex development and manufacturing cycles." Andelyn chose TDP for its unique ability to harmonize data from building & facilities systems, lab instruments, and process & manufacturing equipment. By replatforming the data to a future-proof managed cloud environment, Andelyn will benefit from enhanced GMP compliance and data integrity, improved time-to-value, and lower TCO. Additionally, with an open data cloud platform powered by TDP and the Tetra Partner Network, Andelyn will be able to leverage their preferred tooling for analytics while supporting their customers' data consumption needs. "We're excited to partner with Andelyn Biosciences on their mission-critical data cloud initiative and accelerate their journey towards becoming a digital company," stated Chad Garrett, TetraScience CRO. "As an innovator in providing cloud-native development and manufacturing services to its customers, Andelyn Biosciences recognizes that harmonizing scientific data in the cloud and making it easily accessible to clients will transform the way CDMOs exchange data with clients." Andelyn's initial deployment of TDP is focused on acquiring and harmonizing historical data across key sources while enabling enhanced data search capabilities. Moving forward, Andelyn expects to complete the rollout of the Connected Plant with additional data sources and instruments, and ultimately launch a groundbreaking digital CDMO experience for their customers. About Andelyn Biosciences, Inc. Andelyn Biosciences is a pioneering gene therapy company born out of Nationwide Children's Hospital, where the first FDA-approved systemic gene therapy was discovered. Andelyn is named in honor of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children's Hospital 8-year-old Andrew and 8-week-old Evelyn. Bringing together more than 15 years of experience in AAV vector manufacturing, Andelyn is a full-spectrum Contract Development Manufacturing Organization (CDMO) that helps pioneer solutions that turn hope into reality. Our mission is to accelerate the development and manufacturing of innovative therapies to bring more treatments to more patients. We accomplish this by bringing scalability, capacity, efficiency and expert resources to manufacturing matrices, all to advance the development of viral vector-based therapeutics. Our capabilities include viral vector process and analytical development, small to large scale GMP manufacturing, fill/finish and QC/QA release testing through Phase III with plans to launch commercial services in 2022. Andelyn also offers plasmid manufacturing services, formulation development services and regulatory support.

Read More

RESEARCH

TetraScience R&D Data Cloud Selected by Leading Clinical-Stage Biotechnology Company

TetraScience | September 03, 2021

TetraScience, the R&D Data Cloud company, announced today that Zymeworks Inc. has selected the Tetra Data Platform (TDP) to standardize and automate scientific data flow. As a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics, Zymeworks' R&D engine generates and analyzes large amounts of scientific data in its quest to revolutionize drug design. "In order to take advantage of innovative data science applications including AI/ML, it's important to start with harmonizing R&D data in the cloud," stated Chad Garrett, TetraScience CRO, "We're excited to partner with Zymeworks on their data cloud initiative and help them deliver on their mission to enable patients to return home to their loved ones, disease free." The initial Zymeworks deployment of Tetra Data Platform is in production and integrated with key systems and instruments supporting critical lab workflows. By automating and standardizing the flow of data across all sources and targets, the Tetra R&D Data Cloud will deliver faster and richer insights for Zymeworks' scientists. Additionally, Zymeworks will benefit from cloud-native architecture with greater uptime, security, redundancy, governance, and archival capabilities. About TetraScience TetraScience is the R&D Data Cloud company with a mission to transform life sciences R&D, accelerate discovery, and improve and extend human life. The Tetra R&D Data Cloud provides life sciences companies with the flexibility, scalability, and data-centric capabilities to enable easy access to centralized, harmonized, and actionable scientific data and is actively deployed across enterprise pharma and biotech organizations. As an open platform, TetraScience has built the largest integration network of lab instruments, informatics applications, CRO/CDMOs, analytics, and data science partners, creating seamless interoperability and an innovation feedback loop that will drive the future of life sciences R&D.

Read More